PACIRA BIOSCIENCES INC (PCRX) Stock Price & Overview
NASDAQ:PCRX • US6951271005
Current stock price
The current stock price of PCRX is 23.29 USD. Today PCRX is up by 0.13%. In the past month the price increased by 8.44%. In the past year, price increased by 1.71%.
PCRX Key Statistics
- Market Cap
- 943.012M
- P/E
- 8.86
- Fwd P/E
- 7.59
- EPS (TTM)
- 2.63
- Dividend Yield
- N/A
PCRX Stock Performance
PCRX Stock Chart
PCRX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PCRX. When comparing the yearly performance of all stocks, PCRX is a bad performer in the overall market: 70.48% of all stocks are doing better.
PCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PCRX. PCRX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
PCRX Earnings
On February 26, 2026 PCRX reported an EPS of 0.57 and a revenue of 196.87M. The company missed EPS expectations (-38.21% surprise) and missed revenue expectations (-3.7% surprise).
PCRX Forecast & Estimates
13 analysts have analysed PCRX and the average price target is 30.31 USD. This implies a price increase of 30.14% is expected in the next year compared to the current price of 23.29.
For the next year, analysts expect an EPS growth of 16.65% and a revenue growth 7.11% for PCRX
PCRX Groups
Sector & Classification
PCRX Financial Highlights
Over the last trailing twelve months PCRX reported a non-GAAP Earnings per Share(EPS) of 2.63. The EPS decreased by -18.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.97% | ||
| ROA | 0.56% | ||
| ROE | 1.01% | ||
| Debt/Equity | 0.54 |
PCRX Ownership
PCRX Latest News, Press Relases and Analysis
PCRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.22 | 929.285B | ||
| JNJ | JOHNSON & JOHNSON | 20.85 | 582.039B | ||
| MRK | MERCK & CO. INC. | 22.3 | 285.833B | ||
| PFE | PFIZER INC | 8.92 | 151.141B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.42 | 120.315B | ||
| ZTS | ZOETIS INC | 16.68 | 48.807B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.96 | 26.334B | ||
| VTRS | VIATRIS INC | 5.4 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.11 | 11.405B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.983B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.157B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.94B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.44 | 4.046B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PCRX
Company Profile
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 829 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Company Info
IPO: 2011-02-03
PACIRA BIOSCIENCES INC
2000 Sierra Point Parkway, Suite 900
Brisbane California CALIFORNIA 07054 US
CEO: David Stack
Employees: 829
Phone: 16502428052
PACIRA BIOSCIENCES INC / PCRX FAQ
What does PACIRA BIOSCIENCES INC do?
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 829 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
What is the current price of PCRX stock?
The current stock price of PCRX is 23.29 USD. The price increased by 0.13% in the last trading session.
Does PACIRA BIOSCIENCES INC pay dividends?
PCRX does not pay a dividend.
What is the ChartMill rating of PACIRA BIOSCIENCES INC stock?
PCRX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of PACIRA BIOSCIENCES INC (PCRX) based on its PE ratio?
The PE ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.86. This is based on the reported non-GAAP earnings per share of 2.63 and the current share price of 23.29 USD.
How many employees does PACIRA BIOSCIENCES INC have?
PACIRA BIOSCIENCES INC (PCRX) currently has 829 employees.
What is the outstanding short interest for PACIRA BIOSCIENCES INC?
The outstanding short interest for PACIRA BIOSCIENCES INC (PCRX) is 21.57% of its float.